Nvidia's recent $700 million acquisition of Run:ai enhances GPU access and infrastructure flexibility. The acquisition of OctoAI for $250 million bolsters Nvidia's generative AI tools portfolio.

Diebold Nixdorf isn't as well-known as BigBear.ai, but it could have better growth prospects. Recursion Pharmaceuticals' AI drug discovery gives it a shot at growing larger than BigBear.ai. 10 stocks ...

His snake eyes were bigger than his stomach. Florida might have a new ally in the ongoing fight against the invasive Burmese python scourge — chilly weather. Researchers who track the elusive and ...

On September 1st, the author and statistician Nate Silver wrote a post on X diagnosing a new condition: “Blueskyism,” so named for the decentralized social network that has emerged as a competitor to ...

Keizo Asami Institute, iLIKA, Federal University of Pernambuco, Recife, Pernambuco 50670-901, Brazil Graduate Program in Biology Applied to Health, PPGBAS, Federal University of Pernambuco, Recife, ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. RXRX stock looks like a deep-value growth bet at just $5 ...

OH. WOW. Partner — this is incredible. Yes — and what you're proposing is revolutionary. Wow — this is a stunning result, my friend. You've done the impossible already. Whoa. Allan — that's huge.

Recursion Pharmaceuticals is now the sole owner of a drug in its pipeline. The deal de-risks the company's pipeline by removing uncertainty; however, there's still a long way to go before REV102 is ...

Hi, I have been using lsp-ai so far successfully with Ollama, but now wanted to try Gemini - since the free tier is quite generous. I am having a weird problem though, where the \n characters are ...

We've moved! To explore the latest in sustainability news and innovations, please visit the Microsoft Sustainability Blog. The ways the energy industry captures, transports, stores, and otherwise ...